CJC-1295 in women: dosing, safety, and what the data shows

Last updated 2026-07-26

Has CJC-1295 been studied in women specifically?

No. The primary human data on CJC-1295 comes from a 2006 study by Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism, and it enrolled adult men and women as healthy volunteers, but the paper does not break results out by sex or analyze female-specific pharmacodynamics ^[1]. That trial tested single and multiple-dose administration of CJC-1295 (the long-acting, DAC-conjugated version) and reported sustained increases in GH and IGF-1 over about 6 to 11 days after a single dose, with mean GH elevations lasting roughly a week ^[1]. Beyond that one study, there's no registered clinical trial on ClinicalTrials.gov testing CJC-1295 in a female-only cohort, and no FDA-reviewed data on dosing, safety, or efficacy that is sex-specific. CJC-1295 itself has never been approved by the FDA for any indication; it exists in a regulatory gray zone as a research chemical, and the FDA has flagged similar GHRH-analogue peptides under its guidance on compounded drugs that use bulk substances not on an approved list ^[2]. So when someone asks whether CJC-1295 "works differently" in women, the honest answer is that nobody has run the study. What follows in this article is inference from GH axis physiology that is better studied, not a report of trial results specific to this peptide in women. If you're trying to figure out how to source it at all, the sourcing landscape looks similar regardless of sex: unregulated research-chemical vendors, some sold as "not for human consumption," a small number of compounding pharmacies working under a prescriber. See our overview of how to get CJC-1295 for how those channels actually differ.

Does growth hormone physiology differ between women and men?

Yes, substantially. Women show higher spontaneous GH pulse amplitude and more irregular, higher-frequency secretion than men across the menstrual cycle, largely driven by estrogen's effect on the hypothalamic-pituitary axis ^[3]. Research on GH secretory dynamics, including work summarized by endocrine physiology reviews, shows that estrogen increases GH pulse mass and can blunt IGF-1 generation in the liver relative to circulating GH, meaning women often run higher GH levels for a given IGF-1 output than men do ^[3]. This matters for anyone using a GHRH analogue like CJC-1295. If a compound's whole mechanism is to amplify the natural GH pulse (which is what CJC-1295 does, since it's a GHRH receptor agonist, not a direct GH replacement), then baseline differences in pulsatility could plausibly change the response curve between sexes. Nobody has measured this directly for CJC-1295. It's an extrapolation from the broader GH axis literature, not a peptide-specific finding. Oral estrogen use is a separate, better-documented variable. Oral estrogen (as in some hormone therapy and some oral contraceptives) passes through the liver first and has a known dose-dependent suppressive effect on hepatic IGF-1 generation, an effect that transdermal estrogen doesn't produce to the same degree, according to endocrine physiology literature reviewed by the Endocrine Society ^[3]. Anyone on oral estrogen therapy who is also considering a GH secretagogue is adding a variable that has real documented pharmacology behind it, even though it hasn't been tested in combination with CJC-1295 specifically.

What is the difference between CJC-1295 with DAC and without DAC?

DAC stands for Drug Affinity Complex, a modification that lets the peptide bind to albumin in the blood, extending its half-life from minutes to days. The original Teichman study measured a half-life of about 6.8 days for CJC-1295 with DAC after a single subcutaneous dose, and documented sustained GH and IGF-1 elevation for 6 to 11 days ^[1]. CJC-1295 without DAC is really a different compound in practical terms. It's often sold under that name but it's chemically closer to tetrasubstituted GRF(1-29), also called Mod GRF 1-29 or sermorelin-analogue, with a half-life measured in minutes rather than days ^[4]. This version needs multiple daily injections to produce a pulsatile GH signal that more closely mimics natural secretion, while the DAC version gives one sustained elevated plateau instead of pulses. Neither version has female-specific dosing data. The distinction matters for women mainly in the same way it matters for men: DAC versions produce continuous, non-pulsatile GH elevation that some researchers argue works against the body's natural episodic secretion pattern, while no-DAC versions try to preserve pulsatility at the cost of injection frequency. For the full comparison of pharmacokinetics and practical tradeoffs, see CJC-1295 DAC or no DAC. | Feature | CJC-1295 with DAC | CJC-1295 no-DAC (Mod GRF 1-29) |

Why is CJC-1295 often paired with ipamorelin, and does that change anything for women?

CJC-1295 is a GHRH receptor agonist. Ipamorelin is a ghrelin receptor agonist (a GH secretagogue in the older nomenclature). They act on two separate receptors that both converge on pituitary GH release, so the rationale for combining them is additive or synergistic stimulation through non-overlapping pathways, a concept with real basis in GH physiology research showing that GHRH and GH-secretagogue-receptor agonists produce greater GH release together than either alone in several human and animal studies ^[5]. That rationale is mechanistic, not a proven clinical outcome for this specific combination in women. Studies combining a GHRH analogue with a ghrelin-receptor agonist have generally been small, short-term pharmacodynamic studies measuring GH and IGF-1 levels, not long-term trials measuring body composition, bone density, or symptom outcomes in a female population ^[5]. Nothing in the literature confirms that stacking these two peptides produces a specific benefit in women beyond what's seen in mixed-sex GH secretagogue research generally. Ipamorelin is generally described as more selective for the GH receptor pathway with less effect on cortisol and prolactin compared to older secretagogues like GHRP-6, based on early receptor-binding and animal studies ^[6]. That selectivity claim comes mostly from preclinical and early-phase data, not from large trials in women. If you're weighing whether the combination makes sense for you, the honest framing is: the biological logic for combining a GHRH analogue and a ghrelin agonist is sound and well described in endocrinology literature, but "sound biological logic" is not the same claim as "proven to do X in women." Treat it as a plausible mechanism, not a settled result.

What doses are typically used, and is there a women-specific protocol?

There's no published women-specific dosing protocol, because there's no published clinical trial establishing one. What exists comes from the single-dose and multiple-dose ranges tested in the 2006 human study, which used doses up to 60 mcg/kg and 90 mcg/kg in single-dose cohorts and lower repeated doses in a multi-dose arm, given subcutaneously, without dose adjustment by sex reported in the paper ^[1]. Much of what circulates online as a "female dosing protocol" (commonly cited numbers like 100 mcg twice daily for no-DAC, or 1-2 mg weekly for DAC) comes from bodybuilding forums and anecdotal peptide-community sources, not from any published pharmacokinetic study. Those numbers may or may not be reasonable extrapolations from the trial doses, but they are not validated, and nobody has published safety or efficacy data at those specific doses in a female cohort. Because CJC-1295 isn't FDA-approved and isn't manufactured under a monograph with an approved label, there's no package insert or FDA-reviewed dosing table to check the internet numbers against. Anyone using it should treat every dosing figure they read online, including on peptide-community sites, as unverified until proven otherwise. For practical handling questions once you have a vial in hand (how to mix it, how much bacteriostatic water to use, how to store it), see CJC-1295 reconstitution and CJC-1295 storage and shelf life. Neither of those pages will tell you a female-specific dose either, because that data doesn't exist yet.

Are there safety risks specific to women using CJC-1295?

The general safety profile reported in the 2006 human study included injection site reactions, flushing, and some reports of headache and nausea, none reported as sex-differentiated in the paper ^[1]. Beyond that trial, safety data is thin across the board, and there's no dedicated female-safety literature. Two physiologic considerations are worth naming even though neither has been tested with CJC-1295 directly. First, elevated GH and IGF-1 signaling has a documented relationship with insulin sensitivity; sustained GH elevation can reduce insulin sensitivity, an effect described in growth hormone deficiency treatment literature and in studies of GH excess conditions like acromegaly, and this effect is not shown to differ by sex in a clinically meaningful way in the endocrine literature reviewed by NIH's National Institute of Diabetes and Digestive and Kidney Diseases ^[7]. Anyone with prediabetes, PCOS-related insulin resistance, or a personal history of gestational diabetes should treat that interaction as a real, biologically grounded concern, not a hypothetical one. Second, pregnancy and breastfeeding. There is no safety data on CJC-1295 in pregnancy, and GH axis manipulation during pregnancy is generally avoided in legitimate endocrine practice because of the placenta's own GH-variant secretion and the fetal risks of altering maternal metabolic hormone levels, a concern reflected in how the American College of Obstetricians and Gynecologists and standard endocrinology practice treat GH-related therapies during pregnancy as contraindicated absent a specific approved indication ^[8]. There is no scenario in current medical guidance where an unapproved GHRH analogue is considered acceptable in pregnancy or lactation. Long-term cancer risk from sustained IGF-1 elevation is a live question in the broader GH-therapy literature, with epidemiological studies showing associations between higher IGF-1 levels and certain cancer risks, though causation and magnitude are still debated in endocrine and oncology research . This isn't sex-specific in the data that exists, but it's the kind of open question that should weigh into anyone's decision, male or female, especially with off-label long-term use where there's no monitoring structure in place.

Could CJC-1295 affect the menstrual cycle or fertility?

There's no published data answering this directly. GH and IGF-1 do interact with reproductive hormone signaling, since IGF-1 has a documented role in ovarian follicle development and is studied as an adjunct in some fertility treatment protocols under physician supervision, per reproductive endocrinology literature . That's a real mechanistic link, but it runs in the opposite direction from what most CJC-1295 users are hoping for: it means GH axis manipulation could theoretically interact with cycle regulation, not that it has any established benefit for fertility outside monitored medical protocols using approved GH products. Nobody has published a study tracking menstrual cycle changes, ovulation, or fertility markers in women using CJC-1295. If a cycle change happens while using it, there's no dataset to check it against, and it would be reasonable for a prescriber or gynecologist to want to rule out other causes rather than assume the peptide caused it, precisely because the connection has never been studied.

How does CJC-1295 compare to approved GH therapies for women, like those used in GH deficiency treatment?

FDA-approved recombinant human growth hormone (somatropin) products are approved for adult GH deficiency, and the diagnostic and dosing protocols for those come from real clinical trials that did enroll and analyze outcomes in women, sometimes with sex-specific dosing notes; for instance, some GH deficiency treatment guidance notes that women, particularly those on oral estrogen, often require higher GH doses to reach the same IGF-1 target as men, a finding described in Endocrine Society clinical practice guidelines on adult GH deficiency ^[3]. That's an important contrast. Approved GH therapy has a body of sex-specific evidence guiding dose titration. CJC-1295 has none. If the actual goal is treating diagnosed adult GH deficiency, the evidence-based path runs through an endocrinologist, a stimulation test, and an FDA-approved somatropin product, not through an unapproved GHRH analogue bought without a diagnosis. CJC-1295 was designed as a research tool to study sustained GHRH receptor stimulation, and the 2006 trial that established its pharmacokinetics was explicitly a phase 1 style study, not a treatment trial for any diagnosed condition ^[1].

Is CJC-1295 legal to buy and use in the US?

CJC-1295 is not FDA-approved for any use, and it's not on the FDA's list of bulk drug substances that compounding pharmacies may legally use under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act; the FDA has specifically listed several GHRH-analogue peptides, and evaluated them, in its nomination review process for the 503A bulk substances list, and CJC-1295 has appeared among substances the agency has flagged with safety concerns rather than approved for compounding ^[2]. That means most legitimate compounding pharmacies in the US will not legally prepare it for patient use, and most of what's sold online is labeled "research use only," which is a legal fiction when the buyer's intent is self-administration. This is true regardless of sex. There's no separate legal pathway or exemption for women. If you want to look at what a provider-reviewed sourcing path actually looks like versus a bare research-chemical vendor, see CJC-1295 for sale. CJC-1295 Co reviews providers and can point you toward a pharmacy partner working under physician oversight rather than an unregulated peptide shop, which is a meaningfully different risk profile even though the underlying compound's regulatory status doesn't change.

What should a woman actually consider before starting CJC-1295?

Start with why. If the goal is treating a diagnosed GH deficiency, an approved somatropin product with real trial data (including sex-specific dosing guidance) is the evidence-based route, and that conversation belongs with an endocrinologist ^[3]. If the goal is general anti-aging or body composition change without a diagnosis, be clear-eyed that this is unapproved use of a compound whose sourcing is largely unregulated and whose human data comes from one small mixed-sex pharmacokinetic study from 2006 ^[1]. Get the injection basics right regardless of what you decide: correct site rotation reduces local irritation and lipohypertrophy risk, covered in our guide to CJC-1295 injection sites. And if you're already committed to sourcing it, insist on a provider that reviews the product and works with a real pharmacy rather than a research-chemical storefront with no quality oversight. Flag anything relevant to your own health history before starting: insulin resistance or PCOS, any personal or family cancer history involving hormone-sensitive tumors, pregnancy or breastfeeding status, and current oral estrogen use, since all four interact with GH/IGF-1 physiology through mechanisms that are well documented even though CJC-1295 itself hasn't been tested against them directly ^[3][7].

Frequently asked questions

Is CJC-1295 FDA approved for women or anyone else?

No. CJC-1295 has never received FDA approval for any indication, in women or men. The main human data comes from a single 2006 phase 1 style pharmacokinetic study, and the FDA has flagged it among peptides not permitted for compounding under current bulk substance list review.

Does CJC-1295 affect estrogen or the menstrual cycle?

No study has measured this directly. GH and IGF-1 do interact with ovarian and reproductive hormone signaling in general endocrine literature, so a theoretical interaction with cycle regulation is plausible, but nobody has published data tracking cycle changes in women using CJC-1295 specifically.

Can women use the same CJC-1295 dose as men?

There's no published sex-specific dosing study to compare against. The 2006 human trial used doses up to 60 to 90 mcg/kg in a mixed-sex cohort without reporting sex-based differences, so most "women's dosing" numbers circulating online come from forums, not trials.

Is CJC-1295 with DAC or without DAC better for women?

Neither has female-specific data. DAC versions give sustained GH elevation over days from one injection; no-DAC versions give a short pulse needing daily dosing. The choice is about pulsatile versus sustained GH release, not about sex, and neither version has a dedicated women's trial behind it.

Why is CJC-1295 combined with ipamorelin?

CJC-1295 stimulates the GHRH receptor and ipamorelin stimulates the separate ghrelin receptor; combining agonists from two different pathways has shown additive GH release in small pharmacodynamic studies. That's a real mechanistic rationale, not proof of a specific clinical benefit from the combination in women.

Can CJC-1295 cause insulin resistance in women?

Sustained GH and IGF-1 elevation is documented to reduce insulin sensitivity in general endocrine literature, an effect not shown to be sex-specific. Women with PCOS, prediabetes, or a history of gestational diabetes should treat this as a real, biologically grounded risk rather than a hypothetical one.

Is CJC-1295 safe during pregnancy or breastfeeding?

There's no safety data on CJC-1295 in pregnancy or lactation, and standard endocrine and obstetric practice treats GH-axis manipulation during pregnancy as something to avoid outside an approved, specifically indicated therapy. There is no scenario where an unapproved GHRH analogue is considered acceptable in pregnancy.

Does oral estrogen change how CJC-1295 works?

Nobody has tested that combination directly. Oral estrogen is documented to suppress hepatic IGF-1 generation in a dose-dependent way, an effect not seen to the same degree with transdermal estrogen, so oral estrogen use is a real physiological variable worth flagging to any prescriber even without peptide-specific data.

How is CJC-1295 different from approved growth hormone therapy?

Approved recombinant GH (somatropin) products have trial data supporting sex-specific dosing, including guidance that women on oral estrogen often need higher doses to hit the same IGF-1 target as men. CJC-1295 has no comparable trial base and no approved label or dosing guidance.

What are the real risks of buying CJC-1295 online as a woman?

The risks are the same regardless of sex: unregulated manufacturing, mislabeled concentration, contamination, and no legal pharmacy oversight when bought from research-chemical vendors. A provider-reviewed sourcing route through a real pharmacy partner reduces those specific risks, though it doesn't change CJC-1295's unapproved regulatory status.

Are there any published side effects specific to women?

The 2006 human trial reported injection site reactions, flushing, headache, and nausea without breaking results out by sex. There is no published dataset of side effects specific to women using CJC-1295, so anecdotal reports online should not be treated as established safety data.

Can CJC-1295 help with menopause symptoms?

No clinical trial has tested CJC-1295 for menopause symptoms. Any claim connecting it to hot flashes, bone density, or menopausal body composition change is extrapolation from general GH physiology research, not a result demonstrated for this peptide in a menopausal population.

Sources

1. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism (2006): CJC-1295 human pharmacokinetic and GH/IGF-1 response data, half-life ~6.8 days, mixed-sex cohort
2. Endocrine Society, Clinical Practice Guideline: Evaluation and Treatment of Adult Growth Hormone Deficiency: Sex differences in GH pulsatility, estrogen effects on IGF-1 generation, and women's GH dosing needs on oral estrogen
3. Sigma-Aldrich / peptide reference data on Mod GRF 1-29 (tetrasubstituted GRF 1-29): Short half-life of non-DAC GHRH(1-29) analogue relative to DAC-conjugated form
4. Clemmons DR, Growth hormone secretagogue and GHRH synergy studies, endocrine literature: Additive GH release from combined GHRH agonist and ghrelin-receptor agonist administration
5. Raun K et al., European Journal of Endocrinology, ipamorelin receptor selectivity study: Ipamorelin's selective GH release with minimal cortisol and prolactin effect in early studies
6. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Growth Hormone and Insulin Resistance: GH/IGF-1 excess reduces insulin sensitivity, documented in acromegaly and GH-treatment literature
7. American College of Obstetricians and Gynecologists, Medication Use During Pregnancy: Standard practice avoids unapproved hormone-axis therapies during pregnancy absent specific indication
8. Reproductive endocrinology literature on IGF-1's role in ovarian follicle development: IGF-1 involvement in ovarian follicular development and use as fertility treatment adjunct under supervision